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Abstract. Xanthorrhizol is a sesquiterpenoid compound
extracted from Curcuma xanthorrhiza, which is known locally
as Temulawak. Traditionally, C. xanthorrhiza was found to
have antibacterial, anticancer and anti-inflammatory activity.
The rhizome has also been used to treat inflammation in
postpartum uterine bleeding. An antiproliferative assay using
methylene blue staining revealed that xanthorrhizol inhibited
the proliferation of the cervical cancer cell line HeLa with an
EC50 value of 6.16 Ìg/ml. Xanthorrhizol significantly increased
apoptosis in HeLa cells, as evaluated by the Tdt-mediated
dUTP nick end-labelling (TUNEL) assay and nuclear
morphology by Hoechst 33258 staining. Western blot analysis,
which was further confirmed by the immunostaining results,
implied an up-regulation of tumor suppressor protein p53 and
the pro-apoptotic protein Bax, following the treatment with
xanthorrhizol. Xanthorrhizol, however, did not affect the
expression of the anti-apoptotic protein, Bcl-2 and the viral
oncoprotein, E6. Hence, xanthorrhizol is a promising
antiproliferative and anticancer agent which induces p53 and
Bax-dependent apoptosis in HeLa cervical cancer cells.
Curcuma xanthorrhiza Roxburgh (Roxb.) is well known as a
remedy for various ailments. It can also be taken as a
nutritional supplement. The oil of C. xanthorrhiza is made up
of mainly sesquiterpenoids of which xanthorrhizol (44.5%)
is the major constituent (1). According to Yasni et al., the
major component (approximately 65%) of the essential oils
was identified as ·-curcumene by chromatography - mass
spectrometry (2). On the contrary, the analysis done by
Zwaving and Bos revealed that the essential oil consists of
ar-curcumene (41.4%) and xanthorrhizol (21.5%) (3).
According to Itokawa et al., xanthorrhizol was one of the
major antitumor constituents when tested on Sarcoma 180
ascites in mice (4). Xanthorrhizol was also found to inhibit
COX-2 or iNOS, which are the important mediators in
inflammation and carcinogenesis, respectively (5), showing
that xanthorrhizol has both anti-inflammatory and
chemopreventive properties. In Thailand, C. xanthorrhiza
dried rhizome has been used to treat inflammation in
postpartum uterine bleeding (6).
Cancer of the uterine cervix is currently the second most
common cancer among females in Malaysia after breast
cancer, with an incidence of 11.6 per 100,000 population.
For the past twenty years, the Annual Reports of the
Ministry of Health recorded an average of 2,200 new cases
per year (Ministry of Health Annual Reports 1980-2000).
This number is higher than the speculated 16 cases per
100,000 females in this country, where the female
population is about 10.5 million (7).
The cervix is very highly threatened by the human
papillomavirus (HPV). High-risk HPVs code for at least 3
proteins for growth stimulation and transformation. These
are E5, E6 and E7 (8). The HPV oncoproteins target p53
protein for degradation, leading to abolition of G1 arrest or
apoptosis in response to ionizing radiation and DNA-
damaging agents (9). Cervical cancer chemotherapy in vivo
improved in cases with high p53 expression in the tumor
tissue (10, 11). Apoptosis is the ability of a cell to self-
destruct by the activation of an intrinsic cellular program
when the cells are seriously damaged or no longer needed.
There is much evidence to show that most cancer therapy
drugs kill tumor cells through apoptosis (12). Bax is a
protein from the Bcl-2 family, which has been associated
with apoptotic cell death in vitro and in vivo. The ratio of
various Bcl-2 family members control apoptosis (13).
Over the past 10 years, research for new drugs to be used
in oncology has refocused on natural products, and many
potent compounds have been obtained including
xanthorrhizol. This research investigated the in vitro
antiproliferative and anticancer activity of xanthorrhizol
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against the cervical cancer cell line HeLa, as well as the
mechanism of its action.
Materials and Methods
Cell culture. HeLa (HPV 18-positive), Chang’s Liver and MDBK
were obtained from the American Type Culture Collection
(ATCC) and cultured under standard conditions (95% air, 5% CO2
at 37ÆC) in Dulbecco’s modified Eagle Medium (DMEM),
containing 5% fetal calf serum (FCS), fungizone and antibiotics.
Xanthorrhizol was obtained from the Center for Engineering and
Pilot Plant (CEPP), University of Technology, Malaysia.
Antiproliferative assay. Parallel cultures of HeLa, Chang’s Liver and
MDBK cells were conducted in 96-well plates, using triplicate wells
for each treatment. Following overnight incubation to allow
attachment and at 70 to 90% confluency, cells were treated for 
72 h with xanthorrhizol, tamoxifen (positive control) and DMSO
(negative control) in the final concentration range 0.02 Ìg/ml to
5.00 Ìg/ml. To measure cell viability, the methylene blue method
was used (14).
Apoptotic index. Staining with Hoechst 33258 was performed as
described elsewhere (15). Cells were grown on microscope slides and
fixed by immersing the slide in 4% methanol-free paraformaldehyde
in phosphate-buffered saline (PBS) for 30 min at 4ÆC. After washing
with PBS, the cells were incubated in Hoechst 33258 (Sigma
Chemical Co., St Louis, USA) at a final concentration of 30 Ìg/ml, at
room temperature for 30 min. Nuclear morphology was then
observed under a fluorescent microscope. DNA fragmentation,
which is the characteristic of apoptotic cells, was evaluated by Tdt-
mediated dUTP nick end-labelling (TUNEL) using the Apoptosis
Detection Kit, Fluorescein (Promega Inc., USA), according to the
manufacturer’s instruction. The cells from four random microscopic
fields were counted to get the percentage of TUNEL-positive cells.
Western blotting. Thirty Ìg of protein from both xanthorrhizol-
treated and untreated cells were separated on 12 -15% SDS-
polyacrylamide gels. After electrophoresis, the proteins were
blotted onto polyvinyl-difluoride (PVDF) membranes (PolyScreen,
NEN Life Sciences, USA). The membranes were dried, preblocked
with 6% non-fat milk in PBS-Tween (0.1%), then incubated with
the primary antibodies (p53, E6, Bcl-2 and Bax) diluted 1: 2000.
The p53 antibody used can detect both wild-type and mutant p53
protein. The secondary antibody used was horseradish peroxidase
labelled to rabbit or mouse IgG. A densitometriy analysis was
performed using a GS 670 Imaging Densitometer with software
Molecular Analyst (BioRad, Hercules, USA) after exposure on a
Kodak OMAT X-ray film. The membranes were reprobed with ‚-
actin antibodies (Sigma) as an internal control and to confirm
equal loading.
Immunostaining. This method was used to detect the expression of
Bax and p53. The cells were fixed on slides and permeabilized with
0.2% Triton X-100 for 20 min at 4ÆC and blocked with 2% FCS in
PBS for 2 h at 37ÆC. Next, the cells were washed and incubated
overnight with anti-Bax and anti-p53 antibodies at a 1:250 dilution
at 4ÆC. Then, the slides were incubated with secondary antibodies
conjugated with FITC. The slides were visualized under a
fluorescence microscope.
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Figure 1. Cytotoxic effects of xanthorrhizol on cell viability. (A) Treatment
of HeLa cells with xanthorrhizol significantly decreased the number of
viable cells in a dose-dependent manner. The EC50 obtained was 6.16
Ìg/ml. The EC50 for non-malignant Chang’s Liver and MDBK cells were
29.17 Ìg/ml and 17.38 Ìg/ml, respectively, which were higher than HeLa.
(B) Treatment with tamoxifen showed the non-cytoselective effect on
HeLa, Chang’s Liver and MDBK with EC50 values of 6.44 Ìg/ml, 4.37
Ìg/ml and 7.65 Ìg/ml, respectively. (c) Treatment with cisplatin was less
effective compared to xanthorrhizol and tamoxifen with EC50 values of 74
Ìg/ml, 15.49 Ìg/ml and 44.67 Ìg/ml for HeLa, Chang’s Liver and MDBK,
respectively. Cytotoxicity was determined by methylene blue assay and was
expressed as mean ± S.E.M of three separate experiments.
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Figure 2. Change of apoptotic morphology and TUNEL labelling in
xanthorrhizol-treated cells. Nuclear morphology was observed by staining
with the nuclear fluorochrome Hoechst 33258 and DNA fragmentation
was identified by TUNEL assay, as described in Materials and Methods.
Cells with condensed and fragmented nuclei and apoptotic bodies were
seen in xanthorrhizol-treated cells for 24 h (B) and 72 h (C), but not in the
cells without treatment (A). No fluorescence was detected in the nucleus of
untreated cells (D) as the cells were not apototic and did not exibit DNA
fragmentation. In cells treated with xanthorrhizol for 24 h (E) and 72 h
(F), fluorescence was detected in the nuclear region, showing the apoptotic
characteristics. (G) Apoptosis levels as analyzed by TUNEL assay.
Xanthorrhizol treatment significantly increased the level of apoptosis in
HeLa cells compared to the controls. Apoptotic cells were counted on at
least four independent slides. Magnification X1000.
Results
Effect of xanthorrhizol on cell viability. Using the
methylene blue assay, the cytotoxicity of xanthorrhizol on
HeLa, Chang’s Liver and MDBK cells are shown in Figure
1. HeLa cells were treated with xanthorrhizol in the
concentration range 0.2 to 50 Ìg/ml. Tamoxifen and
cisplatin were used as positive controls, and DMSO as
negative control. Xanthorrhizol significantly reduced
HeLa cell viability in a dose-dependent manner.
Xanthorrhizol decreased 50% of the HeLa cells’ viability
at 6.16 Ìg/ml. Although it also affected the normal cells,
the EC50 values for normal cells were much higher than
for HeLa cells.
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Figure 3. Western blot analysis of p53, Bax, Bcl-2, E6 and immunostaining
of p53 and Bax proteins in HeLa cells. (A) HeLa cells treated with 6 Ìg/ml
xanthorrhizol for indicated times were resolved on a 15% PAGE and
submitted to Western blotting. p53 and Bax protein expression increased after
6 h following xanthorrhizol treatment, while Bcl-2 and E6 levels were not
altered and remain low throughout the experiment. ‚-actin did not show any
changes indicating equal loading (internal control). (B) Immunostaining of
p53 and Bax proteins showed a low level of p53 and Bax in the untreated
HeLa cells. However, a marked increase in immunofluorescence of both
proteins can be seen after 24-h treatment with xanthorrhizol.
Xanthorrhizol-induced apoptotic cell death. Staining with
Hoechst 33258 showed fragmentation and condensation of
chromatin in HeLa cells treated with 6 Ìg/ml xanthorrhizol
for 24 h and 72 h (Figure 2B & 2C), compared to the
untreated control (Figure 2A). Control cells exibited a
normal nuclear morphology, characterized by a diffuse
chromatin structure and, therefore, light staining. The
fragmented DNA produces 3-OH DNA ends that can be
labelled with fluorescein-12-dUTP using the principle of the
TUNEL assay. The extent of DNA fragmentation was
visualized by labelling the xanthorrhizol-treated cells in a
time-course manner. Apoptotic cells were counted on at
least four independent slides. Each experiment was
repeated at least three times.
Xanthorrhizol up-regulated the Bax and p53 protein expression.
To determine which apoptosis-related proteins are regulated
by xanthorrhizol, the expressions of p53, Bax, Bcl-2 and E6
protein were measured after 6 Ìg/ml xanthorrhizol
treatment for 2, 6, 12 and 24 h in HeLa cells using Western
blot analysis. Exposure of HeLa cells to xanthorrhizol
increased the pro-apoptotic proteins p53 and Bax. However,
the expression of the anti-apoptotic Bcl-2 and E6 did not
show any change in either the control or the treated cells
throughout the treatment period (Figure 3A). The up-
regulation of p53 and Bax by xanthorrhizol was confirmed
by the immunostaining of both proteins (Figure 3B), as well
as Bcl-2 and E6 (data not shown). This result implies that
apoptosis induced by xanthorrhizol may be mediated by the
p53 and Bax pathways in cervical cancer cells.
Discussion
The normal epithelium of the cervix is constantly
undergoing regeneration, which is a maintenance program
for tissue-specific homeostasis by establishing the
equilibrium between cellular proliferation and apoptosis.
Interruption in these processes can let the viral invaders
impair normal cells causing neoplastic transformation. The
cause for poor responsiveness to chemotherapy lies in the
etiopathogenesis of cervical cancer such as HPV infection
and loss of tumor suppressor gene function due to
inactivation of p53 and Rb by HPV-encoded viral
oncoproteins. The restoration of p53 levels could be a
potential strategy to increase responsiveness. However,
various authors have differing views regarding the role of
p53 and chemosensitivity (9, 16, 17).
There is an obvious association between the accumulation
of p53 and both HPV 16/18 infection and expression of the
E6 protein (18). It has been demonstrated that the p53
protein complexes with the HPV 16/18 E6 protein in the
cytoplasm and leads to p53 degradation via ubiquitination
(19, 20). E6 can interfere with the normal function of p53
by its ability to abrogate both the transcriptional activation
and transcriptional repression functions of the gene (21, 22).
In this respect, E6 shows similarity to certain mutant forms
of p53, which also fail to function as transcriptional
regulators themselves and may inactivate the wild-type p53
after oligomerization.
The present study showed that the p53 protein level in
the xanthorrrhizol-treated cells was increased 6 h after the
xanthorrhizol treatment in a time-dependent manner. The
Bax expression, however, was increased after 6 h and
maintained at a higher level than the controls throughout
the experiment. The Bcl-2 and E6 levels were unchanged
and maintained at low levels throughout the experiment.
P53 protein expression was slightly higher in the cells
without treatment compared to 2 h after treatment.
The half-life of the mutant form is 4-6 h, while the wild-
type p53 has a short half-life (6-20 min). Thus, detection of
p53 by immunostaining is often considered to reflect the
mutant form (23, 24). However, this might not be true in all
cases, as the immunocytochemical analysis of the p53
protein varies according to the antibody used. Also, in
cervical cancer, previous studies showed that p53 gene
mutation was infrequent (25, 26). In a mutant-specific p53
analysis of cervical cancer tissues, only 12 out of 230
samples studied were found to be positive (18). The
function of normal p53 can be attenuated by E6 of high-risk
HPVs, or possibly by other endogenous proteins such as
MDM-2, resulting in a functionally inactive form.
From this study, it is suggested that xanthorrhizol induced
apoptosis in HeLa cells by up-regulating p53 protein levels
and therefore increased the expressions of both p53 and Bax
proteins, while suppressing Bcl-2 protein. Several lines of
evidence demonstrate the mechanism by which p53 induces
apoptosis. P53 may regulate the gene product of the pro-
apoptotic protein Bax via transcriptional activation (27). A
previous study also showed that p53 can transcriptionally
repress the expression of anti-apoptotic Bcl-2 (28). Utilizing
a temperature-sensitive version of p53, conditional
restoration of p53 activity in a p53-deficient leukemia cell
line resulted in decreased Bcl-2, increased Bax and
stimulated apoptosis (28, 29). The product of the Bax gene
has antagonistic effects over the Bcl-2 protein, and Bax
expression accelerates apoptosis (30).
The promoter of the human Bax gene has been shown to
contain several consensus sequences for p53 binding and is
strongly transactivated by p53. Thus, the effects of p53 on
apoptosis may be mediated, in part, through its effect on the
expression of Bcl-2 and Bax (27). However, the
transcriptional activation of p53 target genes and de novo
synthesis of their products are not obligatory for p53 to
induce apoptosis in certain experimental models. In the
presence of actinomycin D or cycloheximides, which block
RNA synthesis, p53-mediated apoptosis still occurred (31). 
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Since anticancer agents can kill tumor cells through
apoptosis, the increase in p53 and Bax protein expression may
restore sensitivity to apoptotic stimuli in cervical cancer cells.
The results of this study provided evidence that xanthorrhizol
from C. xanthorrhiza was able to inhibit the proliferation of
HeLa cervical cancer cells by inducing apoptotic cell death.
Additional studies are necessary to determine the downstream
effector molecules in the apoptotic pathway. Understanding
the functional role of apoptotic events and their regulation by
interfering pathways will provide new insights into
mechanisms involved in malignant cell proliferation and
avenues to combat malignancy.
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